Jing Wu1, David M Lubman1, Subra Kugathasan2, Lee A Denson3, Jeffrey S Hyams4, Marla C Dubinsky5, Anne M Griffiths6, Robert N Baldassano7, Joshua D Noe8, Shervin Rabizadeh9, Ajay S Gulati10, Joel R Rosh11, Wallace V Crandall12, Peter D R Higgins13, Ryan W Stidham13. 1. Department of Surgery, University of Michigan, Ann Arbor, Michigan, USA. 2. Division of Pediatric Gastroenterology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA. 3. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. 4. Division of Digestive Diseases, Hepatology, and Nutrition, Department of Pediatrics, Connecticut Children's Medical Center, Hartford, Connecticut, USA. 5. Department of Pediatrics, Division of Gastroenterology and Nutrition, Icahn School of Medicine, Mount Sinai New York, New York, USA. 6. Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, the Hospital for Sick Children, University of Toronto, Toronto, Canada. 7. Division of Pediatric Gastroenterology, Department of Pediatrics, Children's Hospital of Pennsylvania, Philadelphia, Pennsylvania, USA. 8. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 9. Division of Pediatric Gastroenterology, Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, California, USA. 10. Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 11. Department of Pediatrics, Goryeb Children's Hospital, Morristown, New Jersey, USA. 12. Division of Pediatric Gastroenterology, Department of Pediatrics, Nationwide Children's Hospital, the Ohio State University College of Medicine, Columbus, Ohio, USA. 13. Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Abstract
OBJECTIVES: Avoiding fibrostenotic complications is of paramount concern in the management of Crohn's disease (CD). We sought to investigate the association of candidate biomarkers of fibrosis collected at diagnosis with the future development of fibrostenotic CD. METHODS: Using the Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn's Disease cohort, a multicenter prospective observational pediatric inception cohort, subjects with an inflammatory phenotype (B1) at diagnosis who later converted to a stricturing phenotype (B2) within 3 years were compared with those who remained B1. Serum collected at diagnosis underwent both parallel reaction monitoring-targeted proteomic analysis and conventional enzyme-linked immunosorbent assay for 10 candidate biomarkers of intestinal fibrosis. Cox proportional hazard regression was used for multivariable analysis of time-dependent outcomes. RESULTS: In 116 subjects 58 subjects with verified B1 phenotype at diagnosis who later converted to B2 disease were compared with 58 subjects who remained B1 over 3 years of follow-up. Extracellular matrix protein 1 (ECM1) levels in the upper quartile (hazard ratio [HR] 3.43, 95% confidence limit [CL] 1.33, 8.42) were associated with future fibrostenotic disease. ASCA IgA (HR 4.99, 95% CL 1.50, 16.68) and CBir levels (HR 5.19, 95% CL 1.83, 14.74) were also associated with future intestinal fibrostenosis, although ECM1 continued to demonstrate independent association with conversion to B2 even with adjustment for serologies in multivariable analysis (HR 5.33, 95% CL 1.29, 22.13). CONCLUSIONS: ECM1 and other biomarkers of fibrosis may aid in determining the risk of uncomplicated inflammatory disease converting to B2 stricturing phenotypes in children with CD. Prospective validation studies to verify test performance and optimize clinical utilization are needed before clinical implementation.
OBJECTIVES: Avoiding fibrostenotic complications is of paramount concern in the management of Crohn's disease (CD). We sought to investigate the association of candidate biomarkers of fibrosis collected at diagnosis with the future development of fibrostenotic CD. METHODS: Using the Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn's Disease cohort, a multicenter prospective observational pediatric inception cohort, subjects with an inflammatory phenotype (B1) at diagnosis who later converted to a stricturing phenotype (B2) within 3 years were compared with those who remained B1. Serum collected at diagnosis underwent both parallel reaction monitoring-targeted proteomic analysis and conventional enzyme-linked immunosorbent assay for 10 candidate biomarkers of intestinal fibrosis. Cox proportional hazard regression was used for multivariable analysis of time-dependent outcomes. RESULTS: In 116 subjects 58 subjects with verified B1 phenotype at diagnosis who later converted to B2 disease were compared with 58 subjects who remained B1 over 3 years of follow-up. Extracellular matrix protein 1 (ECM1) levels in the upper quartile (hazard ratio [HR] 3.43, 95% confidence limit [CL] 1.33, 8.42) were associated with future fibrostenotic disease. ASCA IgA (HR 4.99, 95% CL 1.50, 16.68) and CBir levels (HR 5.19, 95% CL 1.83, 14.74) were also associated with future intestinal fibrostenosis, although ECM1 continued to demonstrate independent association with conversion to B2 even with adjustment for serologies in multivariable analysis (HR 5.33, 95% CL 1.29, 22.13). CONCLUSIONS: ECM1 and other biomarkers of fibrosis may aid in determining the risk of uncomplicated inflammatory disease converting to B2 stricturing phenotypes in children with CD. Prospective validation studies to verify test performance and optimize clinical utilization are needed before clinical implementation.
Authors: Jonathan R Dillman; Ryan W Stidham; Peter D R Higgins; David S Moons; Laura A Johnson; Nahid R Keshavarzi; Jonathan M Rubin Journal: J Ultrasound Med Date: 2014-12 Impact factor: 2.153
Authors: Subra Kugathasan; Lee A Denson; Thomas D Walters; Mi-Ok Kim; Urko M Marigorta; Melanie Schirmer; Kajari Mondal; Chunyan Liu; Anne Griffiths; Joshua D Noe; Wallace V Crandall; Scott Snapper; Shervin Rabizadeh; Joel R Rosh; Jason M Shapiro; Stephen Guthery; David R Mack; Richard Kellermayer; Michael D Kappelman; Steven Steiner; Dedrick E Moulton; David Keljo; Stanley Cohen; Maria Oliva-Hemker; Melvin B Heyman; Anthony R Otley; Susan S Baker; Jonathan S Evans; Barbara S Kirschner; Ashish S Patel; David Ziring; Bruce C Trapnell; Francisco A Sylvester; Michael C Stephens; Robert N Baldassano; James F Markowitz; Judy Cho; Ramnik J Xavier; Curtis Huttenhower; Bruce J Aronow; Greg Gibson; Jeffrey S Hyams; Marla C Dubinsky Journal: Lancet Date: 2017-03-02 Impact factor: 79.321
Authors: Kazunari Ishida; Chitrangada Acharya; Blaine A Christiansen; Jasper H N Yik; Paul E DiCesare; Dominik R Haudenschild Journal: Bone Date: 2013-03-23 Impact factor: 4.398
Authors: Laurent Peyrin-Biroulet; Edward V Loftus; Jean-Frederic Colombel; William J Sandborn Journal: Am J Gastroenterol Date: 2009-10-27 Impact factor: 10.864
Authors: Marla C Dubinsky; Subra Kugathasan; Ling Mei; Yoana Picornell; Justin Nebel; Iwona Wrobel; Antonio Quiros; Gary Silber; Ghassan Wahbeh; Lirona Katzir; Eric Vasiliauskas; Ron Bahar; Anthony Otley; David Mack; Jonathan Evans; Joel Rosh; Maria Oliva Hemker; Neal Leleiko; Wallace Crandall; Christine Langton; Carol Landers; Kent D Taylor; Stephan R Targan; Jerome I Rotter; James Markowitz; Jeffrey Hyams Journal: Clin Gastroenterol Hepatol Date: 2008-07-10 Impact factor: 11.382
Authors: Kaisa E Happonen; Tore Saxne; Pierre Geborek; Maria Andersson; Anders A Bengtsson; Roger Hesselstrand; Dick Heinegård; Anna M Blom Journal: Arthritis Res Ther Date: 2012-01-20 Impact factor: 5.156
Authors: Ingrid Jurickova; Erin Bonkowski; Elizabeth Angerman; Elizabeth Novak; Alex Huron; Grayce Akers; Kentaro Iwasawa; Tzipi Braun; Rotem Hadar; Maria Hooker; Sarah Han; David J Cutler; David T Okou; Subra Kugathasan; Anil Jegga; James Wells; Takanori Takebe; Kevin P Mollen; Yael Haberman; Lee A Denson Journal: Inflamm Bowel Dis Date: 2022-07-01 Impact factor: 7.290
Authors: Mahbubul H Shihan; Mallika Kanwar; Yan Wang; Erin E Jackson; Adam P Faranda; Melinda K Duncan Journal: Matrix Biol Date: 2020-03-12 Impact factor: 11.583
Authors: Calen A Steiner; Jeffrey A Berinstein; Jeremy Louissaint; Peter D R Higgins; Jason R Spence; Carol Shannon; Cathy Lu; Ryan W Stidham; Joel G Fletcher; David H Bruining; Brian G Feagan; Vipul Jairath; Mark E Baker; Dominik Bettenworth; Florian Rieder Journal: Clin Gastroenterol Hepatol Date: 2021-06-02 Impact factor: 11.382
Authors: Jie Wang; Sinan Lin; Jonathan Mark Brown; David van Wagoner; Claudio Fiocchi; Florian Rieder Journal: Immunol Rev Date: 2021-05-16 Impact factor: 10.983
Authors: Ryan C Ungaro; Liangyuan Hu; Jiayi Ji; Shikha Nayar; Subra Kugathasan; Lee A Denson; Jeffrey Hyams; Marla C Dubinsky; Bruce E Sands; Judy H Cho Journal: Aliment Pharmacol Ther Date: 2020-11-01 Impact factor: 9.524